Scandinavian Biopharma expands its Nordic vaccine business with the oral typhoid vaccine Vivotif®
Scandinavian Biopharma has entered into a Nordic distribution agreement with Emergent Travel Health for the oral typhoid vaccine Vivotif®. Typhoid fever is a severe and potentially life-threatening infection caused by the Salmonella bacteria.
The Scandinavian Biopharma team is very experienced in marketing and sales of vaccines. Since 1st of January 2020 Scandinavian Biopharma is the local representative for Vivotif® in Sweden, Norway, Denmark and Finland.
Björn Sjöstrand, CEO of Scandinavian Biopharma comments, “We are really excited about our expanded collaboration with Emergent and to strengthen our vaccine portfolio with Vivotif®. This product perfectly supports our commitment to protect travellers from contracting serious diseases”.
For more information, please contact:
Jonas Bengtsson, VP Business Development: +46 70 861 30 03, email@example.com